fig7
Figure 7. Schematic illustration of a BL-193 prodrug nanoassembly that elicits strong antitumor responses while minimizing off-target toxicity. (A) Preparation of PSSF/BL-193 NAs and its action mechanism; (B) Molecular docking simulation of PSSF and BL-193; (C) Cytotoxicity of PPT Sol or PPT/BL-193 Sol against 4T1 cells; (D) In vivo antitumor evaluation, ****P < 0.0001. Reproduced from Ref.[90] with permission from © 2024 Elsevier B.V.
